Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAN03
- Development stage
- Unknown
- Lead developer
- Cantargia
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
CAN03: sourced facts only. name: "The USPTO has now notified Cantargia that they have issued a patent covering the CAN03 antibody." [1] target: "One antibody, CAN03, originally developed as a backup candidate for CAN04, modifies IL1RAP signaling in a unique way" [1] developer: "The USPTO has now notified Cantargia that they have issued a patent covering the CAN03 antibody." [1] stage: "CAN03 is included in the CANxx discovery program." [1] stage: "developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases." [1] modality: "One antibody, CAN03, originally developed as a backup candidate for CAN04, modifies IL1RAP signaling in a unique way" [1]
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on CAN03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAN03.